Non-concurrent controls in platform trials: can we borrow their concurrent observation data?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non-concurrent controls in platform trials: can we borrow their concurrent observation data?
Authors
Keywords
-
Journal
Statistics in Biopharmaceutical Research
Volume -, Issue -, Pages 1-17
Publisher
Informa UK Limited
Online
2023-10-05
DOI
10.1080/19466315.2023.2267502
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How to Use and Interpret the Results of a Platform Trial
- (2022) Jay J. H. Park et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments
- (2022) Bo Huang et al. PHARMACEUTICAL STATISTICS
- A Bayesian model with application for adaptive platform trials having temporal changes
- (2022) Chenguang Wang et al. BIOMETRICS
- On model-based time trend adjustments in platform trials with non-concurrent controls
- (2022) Marta Bofill Roig et al. BMC Medical Research Methodology
- An Economic Perspective on Platform Trials—The Gift and the Curse
- (2022) Olivier Collignon JAMA Network Open
- Collaborative platform trials to fight COVID‐19: methodological and regulatory considerations for a better societal outcome
- (2021) Olivier Collignon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Are restricted mean survival time methods especially useful for noninferiority trials?
- (2021) Boris Freidlin et al. Clinical Trials
- Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats
- (2021) Kim May Lee et al. Trials
- Platform Trials — Beware the Noncomparable Control Group
- (2021) Lori E. Dodd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
- (2021) Rajeshwari Sridhara et al. Statistics in Biopharmaceutical Research
- Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials
- (2021) Chengxing Lu et al. Therapeutic Innovation & Regulatory Science
- Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- (2021) Christopher C Butler et al. Lancet Respiratory Medicine
- On the empirical choice of the time window for restricted mean survival time
- (2020) Lu Tian et al. BIOMETRICS
- Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella and platform trials
- (2020) Olivier Collignon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Restricted mean survival time as a summary measure of time‐to‐event outcome
- (2020) Takahiro Hasegawa et al. PHARMACEUTICAL STATISTICS
- Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
- (2020) David E. Kloecker et al. ANNALS OF INTERNAL MEDICINE
- An Overview of Platform Trials with a Checklist for Clinical Readers
- (2020) Jay J.H. Park et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Including non-concurrent control patients in the analysis of platform trials: is it worth it?
- (2020) Kim May Lee et al. BMC Medical Research Methodology
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- To add or not to add a new treatment arm to a multiarm study: A decision‐theoretic framework
- (2019) Kim May Lee et al. STATISTICS IN MEDICINE
- Design and monitoring of survival trials based on restricted mean survival times
- (2019) Xiaodong Luo et al. Clinical Trials
- Adaptive platform trials: definition, design, conduct and reporting considerations
- (2019) NATURE REVIEWS DRUG DISCOVERY
- Relative rates not relative risks: addressing a widespread misinterpretation of hazard ratios
- (2018) Rinku Sutradhar et al. ANNALS OF EPIDEMIOLOGY
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- (2017) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point
- (2017) Bo Huang et al. PHARMACEUTICAL STATISTICS
- Efficiencies of platform clinical trials: A vision of the future
- (2016) Benjamin R Saville et al. Clinical Trials
- Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
- (2016) Roger P. A’Hern JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials
- (2016) Ludovic Trinquart et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
- (2015) Hajime Uno et al. ANNALS OF INTERNAL MEDICINE
- On the restricted mean survival time curve in survival analysis
- (2015) Lihui Zhao et al. BIOMETRICS
- The Platform Trial
- (2015) Scott M. Berry et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice
- (2015) Dena R Cohen et al. Trials
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Some recommendations for multi-arm multi-stage trials
- (2012) James Wason et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Generating survival times to simulate Cox proportional hazards models with time-varying covariates
- (2012) Peter C. Austin STATISTICS IN MEDICINE
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
- (2011) Patrick Royston et al. STATISTICS IN MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started